Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $278.00. The company’s shares closed yesterday at $227.21.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become a leaner and more focused company. The news was anno ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be announcing earnings results tomorrow before market open. Here’s what to look for. BD beat analysts’ revenue ...

FRANKLIN LAKES, N.J. (AP) — FRANKLIN LAKES, N.J. (AP) — Becton Dickinson and Co. (BDX) on Wednesday reported fiscal first-quarter earnings of $303 million. On a per-share basis, the Franklin ...

StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately ...

In trading on Thursday, shares of Becton, Dickinson & Co (Symbol: BDX) crossed below their 200 day moving average of $233.84, changing hands as low as $232.30 per share. Becton, Dickinson & Co ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

Becton Dickinson (BDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Business: Becton Dickinson develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products for health-care institutions, physicians, life science ...